

# Max Schnurr

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/735935/publications.pdf>

Version: 2024-02-01

37  
papers

1,785  
citations

279798

23  
h-index

361022

35  
g-index

38  
all docs

38  
docs citations

38  
times ranked

2975  
citing authors

#	ARTICLE	IF	CITATIONS
1	Defective Interfering Genomes and the Full-Length Viral Genome Trigger RIG-I After Infection With Vesicular Stomatitis Virus in a Replication Dependent Manner. <i>Frontiers in Immunology</i> , 2021, 12, 595390.	4.8	16
2	T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. <i>Nature Biomedical Engineering</i> , 2021, 5, 1246-1260.	22.5	80
3	OAS1/RNase L executes RIG-I ligand-dependent tumor cell apoptosis. <i>Science Immunology</i> , 2021, 6, .	11.9	19
4	To Protect Fatty Livers from Ischemia Reperfusion Injury: Role of Ischemic Postconditioning. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1349-1359.	2.3	0
5	RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade. <i>Leukemia</i> , 2020, 34, 1017-1026.	7.2	33
6	IL-18 But Not IL-1 Signaling Is Pivotal for the Initiation of Liver Injury in Murine Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8602.	4.1	14
7	Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	35
8	Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2101-2112.	4.2	12
9	Ischemic Postconditioning (IPostC) Protects Fibrotic and Cirrhotic Rat Livers after Warm Ischemia. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-11.	1.9	2
10	Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer. , 2019, 7, 288.		22
11	IFN Regulatory Factor 4 Controls Post-ischemic Inflammation and Prevents Chronic Kidney Disease. <i>Frontiers in Immunology</i> , 2019, 10, 2162.	4.8	16
12	Mitochondrial adaptation in steatotic mice. <i>Mitochondrion</i> , 2018, 40, 1-12.	3.4	54
13	Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies. <i>Scientific Reports</i> , 2018, 8, 8810.	3.3	13
14	Nlrp3-dependent IL-1 $\beta$ inhibits CD103+ dendritic cell differentiation in the gut. <i>JCI Insight</i> , 2018, 3, .	5.0	22
15	Data on chow, liver tissue and mitochondrial fatty acid compositions as well as mitochondrial proteome changes after feeding mice a western diet for 24 weeks. <i>Data in Brief</i> , 2017, 15, 163-169.	1.0	9
16	Cancer cells induce interleukin-22 production from memory CD4 <sup>+</sup> T cells via interleukin-1 to promote tumor growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 12994-12999.	7.1	115
17	Volcanic Ash Activates the NLRP3 Inflammasome in Murine and Human Macrophages. <i>Frontiers in Immunology</i> , 2017, 8, 2000.	4.8	25
18	Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer. <i>Cancer Letters</i> , 2016, 381, 259-268.	7.2	30

#	ARTICLE	IF	CITATIONS
19	Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	96
20	Strategies to relieve immunosuppression in pancreatic cancer. <i>Immunotherapy</i> , 2015, 7, 363-376.	2.0	30
21	Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma. <i>Onc Immunology</i> , 2015, 4, e1029698.	4.6	36
22	Selective Bispecific T Cell Recruiting Antibody and Antitumor Activity of Adoptive T Cell Transfer. <i>Journal of the National Cancer Institute</i> , 2015, 107, 364.	6.3	34
23	Induction of immunogenic cell death by targeting RIG-I-like helicases in pancreatic cancer. <i>Onc Immunology</i> , 2014, 3, e955687.	4.6	12
24	Multifunctional antitumor molecule 5'-triphosphate siRNA combining glutaminase silencing and RIG-I activation. <i>International Journal of Cancer</i> , 2014, 134, 1958-1971.	5.1	34
25	Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8+ T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 321-333.	4.2	32
26	Inflammasome-Dependent and -Independent IL-18 Production Mediates Immunity to the ISCOMATRIX Adjuvant. <i>Journal of Immunology</i> , 2014, 192, 3259-3268.	0.8	69
27	Therapeutic Efficacy of Bifunctional siRNA Combining TGF- $\beta$ 1 Silencing with RIG-I Activation in Pancreatic Cancer. <i>Cancer Research</i> , 2013, 73, 1709-1720.	0.9	130
28	Breaking tumor-induced immunosuppression with 5'-triphosphate siRNA silencing TGF- $\beta$ 2 and activating RIG-I. <i>Onc Immunology</i> , 2013, 2, e24170.	4.6	20
29	An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. <i>International Journal of Cancer</i> , 2011, 128, 897-907.	5.1	72
30	ISCOMATRIX Adjuvant Combines Immune Activation with Antigen Delivery to Dendritic Cells In Vivo Leading to Effective Cross-Priming of CD8+ T Cells. <i>Journal of Immunology</i> , 2011, 187, 55-63.	0.8	105
31	Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery. <i>Blood</i> , 2010, 116, 218-225.	1.4	31
32	Presentation of tumour antigens by dendritic cells and challenges faced. <i>Current Opinion in Immunology</i> , 2010, 22, 137-144.	5.5	42
33	ISCOMATRIX Adjuvant Induces Efficient Cross-Presentation of Tumor Antigen by Dendritic Cells via Rapid Cytosolic Antigen Delivery and Processing via Tripeptidyl Peptidase II. <i>Journal of Immunology</i> , 2009, 182, 1253-1259.	0.8	91
34	Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant. <i>Immunology and Cell Biology</i> , 2009, 87, 371-376.	2.3	64
35	Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. <i>Blood</i> , 2005, 105, 2465-2472.	1.4	175
36	NY-ESO-1 Protein Formulated in ISCOMATRIX Adjuvant Is a Potent Anticancer Vaccine Inducing Both Humoral and CD8+ T-Cell-Mediated Immunity and Protection against NY-ESO-1+ Tumors. <i>Clinical Cancer Research</i> , 2004, 10, 2879-2890.	7.0	84

#	ARTICLE	IF	CITATIONS
37	Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Research, 2002, 62, 2347-52.	0.9	109